

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11188181/publications.pdf>

Version: 2024-02-01

92
papers

5,611
citations

126907

33
h-index

82547

72
g-index

93
all docs

93
docs citations

93
times ranked

6056
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the alcohol, smoking and substance involvement screening test (ASSIST). <i>Addiction</i> , 2008, 103, 1039-1047.	3.3	825
2	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
3	Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. <i>Addiction</i> , 2003, 98, 441-452.	3.3	246
4	Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. <i>Drug and Alcohol Review</i> , 2005, 24, 217-226.	2.1	220
5	The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). <i>Drug and Alcohol Review</i> , 2005, 24, 411-418.	2.1	204
6	Oral substitution treatment of injecting opioid users for prevention of HIV infection. <i>The Cochrane Library</i> , 2011, , CD004145.	2.8	197
7	Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. <i>Addiction</i> , 2008, 103, 1484-1492.	3.3	192
8	Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. <i>Addiction</i> , 1998, 93, 701-711.	3.3	175
9	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	13.7	169
10	A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health care settings in four countries. <i>Addiction</i> , 2012, 107, 957-966.	3.3	167
11	Psychotic symptoms in methamphetamine psychotic in-patients. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 347-352.	2.1	164
12	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008, 103, 462-468.	3.3	161
13	The rise of methamphetamine in Southeast and East Asia. <i>Drug and Alcohol Review</i> , 2008, 27, 220-228.	2.1	128
14	One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). <i>Drug and Alcohol Dependence</i> , 2006, 83, 174-180.	3.2	118
15	Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES). <i>Addiction</i> , 2012, 107, 1998-2008.	3.3	108
16	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. <i>Addiction</i> , 2002, 97, 771-772.	3.3	101
17	Substitution treatment of injecting opioid users for prevention of HIV infection. , 2008, , CD004145.		98
18	Ultra-rapid screening for substance-use disorders: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite). <i>Drug and Alcohol Dependence</i> , 2013, 132, 352-361.	3.2	95

#	ARTICLE	IF	CITATIONS
19	Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 959-964.	4.8	77
20	Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS). <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 255-263.	2.8	76
21	Buprenorphine for managing opioid withdrawal. <i>The Cochrane Library</i> , 2017, 2017, CD002025.	2.8	66
22	Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. <i>Drug and Alcohol Dependence</i> , 2011, 118, 265-273.	3.2	62
23	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005, 16, 67-75.	3.3	55
24	Predictive factors for treatment retention in methadone programs in Indonesia. <i>Journal of Substance Abuse Treatment</i> , 2012, 42, 239-246.	2.8	52
25	Bloody needles. <i>Aids</i> , 1991, 5, 1025-1028.	2.2	50
26	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	3.3	50
27	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
28	Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. <i>Addiction</i> , 2019, 114, 1346-1353.	3.3	45
29	The diversion and injection of a buprenorphine-naloxone soluble film formulation. <i>Drug and Alcohol Dependence</i> , 2014, 136, 21-27.	3.2	43
30	Drug policy in Vietnam: A decade of change?. <i>International Journal of Drug Policy</i> , 2012, 23, 319-326.	3.3	42
31	A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. <i>Drug and Alcohol Dependence</i> , 2002, 68, 5-14.	3.2	41
32	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>The Cochrane Library</i> , 2010, , CD002022.	2.8	41
33	Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008, 48, 248-254.	1.0	35
34	HIV prevalence and risk behaviours for HIV transmission in South Australian prisons. <i>Aids</i> , 1991, 5, 845-852.	2.2	34
35	Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. <i>Addiction</i> , 2003, 98, 413-418.	3.3	33
36	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	1.9	31

#	ARTICLE	IF	CITATIONS
37	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	3.2	29
38	Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. <i>Harm Reduction Journal</i> , 2015, 12, 31.	3.2	28
39	Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. <i>Psychiatry Research</i> , 2016, 238, 166-171.	3.3	28
40	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018, 5, 155-166.	7.4	28
41	Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. <i>Addictive Behaviors</i> , 2005, 30, 443-456.	3.0	23
42	Short-term Outcomes for the Treatment of Heroin Dependence. <i>Addictive Disorders and Their Treatment</i> , 2006, 5, 133-143.	0.5	23
43	Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT). <i>Drug and Alcohol Dependence</i> , 2014, 139, 121-131.	3.2	22
44	Cost-effectiveness of center-based compulsory rehabilitation compared to community-based voluntary methadone maintenance treatment in Hai Phong City, Vietnam. <i>Drug and Alcohol Dependence</i> , 2016, 168, 147-155.	3.2	22
45	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
46	Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. <i>Drug and Alcohol Review</i> , 2011, 30, 613-620.	2.1	21
47	The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine/naloxone film. <i>Drug and Alcohol Review</i> , 2016, 35, 76-82.	2.1	21
48	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 51-61.	2.8	20
49	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015, 110, 226-237.	3.3	19
50	Accidental Fatalities Among Heroin Users in South Australia, 1994-1997: Toxicological Findings and Circumstances of Death. <i>Addiction Research and Theory</i> , 2002, 10, 335-346.	1.9	18
51	The political and scientific challenges in evaluating compulsory drug treatment centers in Southeast Asia. <i>Harm Reduction Journal</i> , 2017, 14, 2.	3.2	18
52	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 536-541.	2.4	17
53	Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 640-7.	2.4	17
54	Overdose Among Heroin Users: Evaluation of an Intervention in South Australia. <i>Addiction Research and Theory</i> , 2001, 9, 481-501.	1.9	15

#	ARTICLE	IF	CITATIONS
55	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 83-91.	2.1	15
56	The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108262.	3.2	15
57	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	3.2	14
58	Outcomes of compulsory detention compared to community-based voluntary methadone maintenance treatment in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2018, 87, 9-15.	2.8	14
59	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. <i>Addiction</i> , 2021, 116, 3139-3152.	3.3	14
60	Correlates of retention on the South Australian Methadone Program 1981-91. <i>Australian and New Zealand Journal of Public Health</i> , 1998, 22, 771-776.	1.8	11
61	Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. <i>Drug and Alcohol Review</i> , 2003, 22, 425-431.	2.1	11
62	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	3.2	11
63	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018, 8, e020723.	1.9	11
64	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. , 2006, , CD002022.		10
65	Methamphetamine Psychosis in Australia, Philippines, and Thailand. <i>Addictive Disorders and Their Treatment</i> , 2010, 9, 143-149.	0.5	10
66	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622.	2.1	10
67	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021, 49, 1774-1775.	1.9	10
68	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	3.2	10
69	Investigation of the Alcohol, Smoking, and Substance Involvement Screening Test (the ASSIST) Version 3.0 in Pregnancy. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 123-135.	0.5	9
70	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
71	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015, 34, 603-610.	2.1	8
72	Latent Psychotic Symptom Profiles Amongst People Who Use Methamphetamine: What Do They Tell Us About Existing Diagnostic Categories?. <i>Frontiers in Psychiatry</i> , 2018, 9, 578.	2.6	8

#	ARTICLE	IF	CITATIONS
73	A randomised controlled trial of a brief intervention for illicit drug use linked to ASSIST screening in a primary healthcare setting: results from the Australian component of the World Health Organization Phase III ASSIST studies. <i>Australian Journal of Primary Health</i> , 2018, 24, 149.	0.9	8
74	A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia. <i>Drug and Alcohol Review</i> , 2022, 41, 309-319.	2.1	8
75	Hepatitis C and the history of injecting drug use in South Australia. <i>Medical Journal of Australia</i> , 1994, 161, 286-286.	1.7	7
76	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	2.1	7
77	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109464.	3.2	7
78	Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015, 34, 623-629.	2.1	6
79	The prescription of methadone for opiate dependence in Australia, 1985-1991. <i>Medical Journal of Australia</i> , 1993, 159, 107-108.	1.7	6
80	Quality of life as a predictor of time to heroin relapse among male residents following release from compulsory rehabilitation centres in Vietnam. <i>Drug and Alcohol Review</i> , 2021, 40, 296-306.	2.1	5
81	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001-2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108354.	3.2	5
82	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1321-1333.	1.9	4
83	HIV infection among injecting drug users in the South Australian methadone program. <i>Medical Journal of Australia</i> , 1995, 162, 242-244.	1.7	4
84	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	3.3	3
85	The Drug Survey App™: a protocol for developing and validating an interactive population survey tool for drug use among Aboriginal and Torres Strait Islander Australians. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 17.	2.6	2
86	The Ultrarapid Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST-Lite) and Implications for Neuropathology. , 2016, , 649-659.		1
87	Strengthening advocacy efforts with empirical evidence: A case example of the conduct, uptake and utilisation of research in drug policy decision-making in Vietnam. <i>International Journal of Drug Policy</i> , 2017, 49, 41-47.	3.3	1
88	End compulsory drug treatment in the Asia-Pacific region. <i>Lancet, The</i> , 2022, 399, 419-421.	18.7	1
89	Brief Intervention for Illicit Drug Users. , 2015, , 293-312.		0
90	Participant perspectives on the Australian WHO ASSIST Phase III brief intervention for illicit drug use in a primary healthcare setting. <i>Australian Journal of Primary Health</i> , 2018, 24, 518.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Response to commentaries. <i>Addiction</i> , 2019, 114, 1357-1358.	3.3	0
92	Brief Intervention for Illicit Drug Use. , 2021, , 655-671.		0